CHANGING THE STANDARD
CARDIALYTICS™
ADVANCING ARRHYTHMIA CARE
Pristine data
See what you’ve been missing.
Precise Analytics
Real-time, automated, AI-based algorithms physicians can trust.
Powerful Decisions
Comprehensive, clinical decision-making simplified.
EP RECORDING. ENHANCED.
It’s time to upgrade the EP lab.
ECGenius™ System represents an evolution in cardiac signal acquisition, interpretation, and therapy support, creating unprecedented opportunities for the integration of AI-based algorithms.
ABOUT CathVision
CathVision’s mission is to help physicians cure cardiac arrhythmia. Committed to empowering physicians to make more informed clinical decisions in the EP lab, CathVision is redefining the necessity of exceptional cardiac electrical signals to diagnose, characterize and treat the most common heart rhythm disorders. The company is focused on developing electrophysiology solutions centered around an innovative EP recording system and AI-based analytic tools.
CathVision began as a graduate-level clinical research project designed to determine necessary improvements to ablation therapy and was officially launched as a company in 2013 in Denmark. The company’s presence has since expanded to the United States with operations in Minnetonka, Minnesota.
history
CathVision highlights PFAnalyzer, post PFA energy calculation measurement method, at HRS 2024.
ECGenius System featured at HRS 2023 Rhythm Theater Symposium and scientific sessions.
Patient enrollment of a follow-on clinical study to demonstrate the value of the Signal Complexity algorithm at OLV Hospital Aalst, led by Dr. Tom De Potter, begins.
CathVision announces key milestones in advance of ECGenius commercial launch.
NYU Langone Health initiates clinical study evaluating the Signal Complexity™ algorithm.
CathVision raises $7.2 million from existing investors to further the advancement of AI-powered analytics and commercialization of the ECGenius™ System
The ECGenius™ System, CathVision’s unique high-fidelity, low-noise EP recording technology, earns FDA clearance.
CathVision enrolls patients in first U.S.-based clinical study at the University of Vermont Medical Center.
CathVision enrolls first patients in PVISION Multicenter Clinical Study at four European hospitals.
CathVision completes an investment round of €13M to begin multi-center clinical studies.
CathVision expands its board of directors and is awarded a €2.2M grant from the Horizon 2020 programs.
CathVision obtains IOS13485 certification and establishes a presence in the U.S.
CathVision closes its first multi-million-dollar round of funding.
CathVision is officially incorporated.
Leadership
Mads Emil Matthiesen
Co-Founder & CEO
Mads Emil Matthiesen
Co-Founder & CEO
- Email:mem@cathvision.com
Rune Ørndrup
Co-Founder
Rune Ørndrup
Co-Founder
Allan Gersfelt-Larsen
VP Engineering
Allan Gersfelt-Larsen
VP Engineering
Board of Directors
Søren Thestrup-Nielsen
Chairman
Søren Thestrup-Nielsen
Chairman
Denis Gestin
Board Member
Denis Gestin
Board Member
Meghna Eichelberger
Board Member
Meghna Eichelberger
Board Member
Tonni Bülow-Nielsen
Board Member
Tonni Bülow-Nielsen
Board Member
Magnus Holm
Board Member
Magnus Holm
Board Member